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Purpose: Evidence supporting the use of dietary
supplements, in particular, multivitamin/multimineral
supplements (MVMS), has been mixed, complicating
the ability of health care professionals to recom-
mend their use. To clarify the role that MVMS can
play in supporting human health, a series of con-
sensus statements was developed based on expert
opinion.
Methods: A panel of 14 international experts in
nutritional science and health care was convened
to develop consensus statements related to using
MVMS in supporting optimal human health. The
modified Delphi process included 2 rounds of remote
voting and a final round of voting at a roundtable
meeting where evidence summaries were presented
and discussed. The level of agreement with each of 9
statements was rated on a 5-point Likert scale: agree
strongly; agree with reservation; undecided; disagree;
or disagree strongly. Consensus was predefined as640≥80% of the panel agreeing strongly or agreeing with
reservation to a given statement.
Findings: Consensus was reached for all statements.
The panel determined that MVMS can broadly im-
prove micronutrient intakes when they contain at least
the micronutrients that are consumed insufficiently or
have limited bioavailability within a specified popula-
tion. MVMS formulations may also be individualized
according to age, sex, life cycle, and/or other selected
characteristics. There are specific biological processes
and health outcomes associated with deficient, inad-
equate, and adequate micronutrient levels. Adequate
intake is necessary for normal biological functioning
required for good health; in some instances, higherVolume 40 Number 4
J.B. Blumberg et al.than recommended micronutrient intakes have the
potential to provide additional health benefits. Meet-
ing daily intakes established by dietary reference
values should be an explicit public health goal for
individuals and populations. Use of MVMS is one
approach to ensure that adequate micronutrient needs
are met in support of biological functions necessary to
maintain health. Long-term use of MVMS not exceed-
ing the upper limit of recommended intakes has been
determined to be safe in healthy adults. There is
insufficient evidence to indicate that MVMS are
effective for the primary prevention of chronic medical
conditions, including cardiovascular disease and can-
cer. However, for certain otherwise healthy subpopu-
lations (eg, pregnant women, older adults) and some
individuals with existing medical conditions who
experience inadequacies in micronutrient intake, ad-
dressing inadequacies by using MVMS can provide
health benefits.
Implications: This consensus panel has described
key issues related to the use of MVMS among
individuals at risk of or presenting with inadequacies
in micronutrient intake or biomarker status. (Clin
Ther. 2018;40:640–657) & 2018 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
Key words: adverse effects, Delphi consensus, diet-
ary supplements, health benefits, multivitamin/multi-
mineral supplements, nutrition.INTRODUCTION
Dietary supplements and, in particular, multivitamin/
multimineral supplements (MVMS), are widely used1;
recent data from the United States suggest that the use
of MVMS is declining, however.1,2 No guidelines
currently exist for recommending the use of MVMS,
and nutritional education and training among health
care professionals (HCPs), including physicians,
nurses, and pharmacists, are limited.3–7 Thus, little
direction is available for HCPs to guide patients in this
area. Results from randomized controlled trials
(RCTs) conducted with MVMS provide conflicting
evidence about their potential benefits in preventing/
treating chronic medical conditions (CMCs), leading
some to question their value, particularly in higher
income countries.8,9 Nonetheless, there is ample evi-
dence from national dietary intake surveys reporting
deficiencies and inadequacies in micronutrient intakeApril 2018and/or status, and correcting these deficiencies can
have health benefits.10,11 To address this conundrum,
an international panel of experts in the areas of
nutritional science and health care was convened to
develop consensus statements that discuss issues re-
garding MVMS use.
An essential component in discussing the role of
dietary supplements involves defining recommended
intakes for maintaining good health. Vitamin and
mineral requirements are defined as the intake needed
to meet a specified indicator of adequacy for each
nutrient.12 The terms commonly used to describe
reference intakes are defined in Figure 1.13 However,
it is important to appreciate that dietary reference
values can vary among countries or regions based on
different criteria and/or approaches to reach consensus.MATERIALS AND METHODS
An international group of 14 experts in nutritional
science and health care was convened to develop a
series of consensus statements that present guidelines
for using MVMS. To ensure that the panel was
composed of a heterogeneous group of experts in
the specialty area and to provide global representation
that would allow for regional variations to be
accounted for in the statements, the consensus panel’s
co-chairs (J.B.B. and H.C.) identified a select number
of participants based on their expertise and geo-
graphic location beginning in November 2016. After
initially contacting the co-chairs, the sponsor (Pfizer
Consumer Healthcare, Madison, New Jersey) had no
involvement in conducting the consensus panel or
preparing the present article.
Once participants were identified, the co-chairs
developed a set of initial questions related to using
MVMS. Each assigned panel member, as selected by
the co-chairs, began searching the literature and
identifying information sources to address these ques-
tions. Where applicable, the methods for conducting
literature reviews are described in the corresponding
evidence summaries. After reviewing the literature,
panelists selected as Statement Leads developed initial
drafts of each statement, which were shared with team
members chosen by the co-chairs to assist in this
effort. The initial 9 statements were then circulated
to the entire panel for a first round of remote
consensus voting. The voting followed a modified
Delphi process,14,15 in which the level of agreement641
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Figure 1. Definitions of terms used to describe components of Dietary Reference Intakes.11 This figure shows
that the Estimated Average Requirement (EAR) is the intake at which the risk of inadequacy is 0.5
(50%) for an individual. The Recommended Dietary Allowance (RDA) is the intake at which the risk
of inadequacy is very small, only 0.02 to 0.03 (2% to 3%). The Adequate Intake (AI) does not bear a
consistent relationship to the EAR or the RDA, because it is set without the estimate of the
requirement. As a result, the AI is not included in this figure. At intakes between the RDA and the
Tolerable Upper Intake Level (UL), the risks of inadequacy and excess are both close to 0. At intakes
above the UL, the risk of adverse effects may increase. AI is the recommended average level of daily
nutrient intake based on observed or experimentally determined approximations of intake by a
group (or groups) of apparently healthy people that are assumed to be adequate; it is used when an
RDA cannot be determined. Mean usual intake at or above this level has a low probability of
inadequacy among individuals or groups. When the AI for a nutrient is not based on mean intakes
of healthy populations, the assessment of adequacy is made with less confidence. EAR is the
average daily nutrient intake level estimated to meet the requirement of one half the healthy
individuals in a particular life stage and sex group; it is used to examine the probability that usual
intake is inadequate in an individual or to estimate the prevalence of inadequate intakes within a
group. Provided certain assumptions are met, the prevalence of inadequate intakes in a group can
be estimated as the percentage of the group’s usual intake distribution that falls below the EAR.
The RDA is the average daily nutrient intake level that is sufficient to meet the nutrient requirement
of nearly all (97%–98%) healthy individuals in a particular life stage and sex group. For nutrients
with normal requirement distributions, the RDA is calculated from the EAR by adding 2 SDs of the
requirement distribution to the EAR. Usual intake at or above the RDA has a low probability of
inadequacy for an individual; it is not to be used to assess intakes of groups. The UL is the highest
average daily nutrient intake level likely to pose no risk of adverse health effects to almost all individuals
in the general population. As intake increases above the UL, the potential risk of adverse effects
increases. Usual intake above this level may place an individual at risk of adverse effects from excessive
nutrient intake; it is used to estimate the percentage of the population at potential risk of adverse
effects from excessive nutrient intake. Adapted with permission of National Academies Press from
Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National
Academies Press; 2000; permission conveyed through Copyright Clearance Center, Inc.
Clinical Therapeuticswas rated on a 5-point Likert scale: agree strongly
(Aþ); agree with reservation (A); undecided (U);
disagree (D); or disagree strongly (Dþ). Consensus
was predefined as ≥80% of the panel rating a given
statement Aþ or A.
After the Statement Leads and their team members
revised the statements, a subsequent round of remote642voting was conducted; the final round of voting was
conducted at an in-person meeting of all panelists in
Philadelphia, Pennsylvania, in June 2017, where the
Statement Leads presented evidence summaries used to
support their statements. The live meeting, which was
moderated by the co-chairs, was included to allow the
panel members to openly discuss the statements. TheVolume 40 Number 4
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Figure 2. Evolution of consensus voting over 3 rounds.
J.B. Blumberg et al.meeting was followed by the final round of anonymous
voting using an automated response system.16 The co-
chairs decided to forego rating the quality of evidence
and strength of recommendations because these criteria
would not be applicable to most statements; where
applicable, the quality of evidence is informally
described. A summary of the consensus voting is
presented in Figure 2.RESULTS
Consensus was reached for all statements. Upon
completion of the in-person meeting, a confidential
poll was conducted and panel members agreed that no
commercial bias was evident in the process before or
during the meeting. Also, all participants provided
adequate input on all statement ratings and recom-
mendations, which are described individually in the
following sections.
1. For the purpose of broad-spectrum micronutrient
supplementation for a general population, MVMS
should contain at least the micronutrients that are
commonly underconsumed relative to their recom-
mended intakes within that country/region. Most of
these vitamins and nutritionally essential minerals
should be present in amounts approximating recom-
mended intakes. Within this context, MVMS may be
safely formulated for large subgroups according to age,
sex, and/or life-cycle–specific micronutrient needs.
Aþ: 64%; A: 36%April 2018There is currently neither consensus nor published
criteria quantifying the doses of micronutrients that
should be included in MVMS. However, several
definitions of MVMS have been proposed. For exam-
ple, the US National Institutes of Health defines
MVMS as: “any supplement containing 3 or more
vitamins and minerals but no herbs, hormones, or
drugs, with each component at a dose less than the
Tolerable Upper Intake Level (UL) determined by the
Food and Nutrition Board—the maximum daily
intake likely to pose no risk for adverse health
effects.”17 The National Institutes of Health classifies
MVMS into subgroups as: (1) “once daily,” which
contain most or all vitamins and essential minerals at
levels approximating the Recommended Dietary
Allowance (RDA) or Adequate Intake (AI); (2) special
formulations designed for specific subpopulations, and
packs containing multiple individual supplements; and
(3) “specialized” formulations that might contain
vitamins and minerals at levels substantially above
the RDA and sometimes the UL.18 In contrast, others
have defined MVMS as dietary supplements providing
≥100% of the RDA or AI for ≥9 to 10 vitamins and
nutritionally essential minerals.2,10,11 Currently avail-
able MVMS do not generally contain the RDA or AI
for calcium, choline, magnesium, potassium, vitamin K,
phosphorus, and others.
Evidence from international databases, review ar-
ticles, and national population-based surveys indicates
that micronutrient intake deficiencies/inadequacies643
Clinical Therapeutics(especially for vitamin A, iron, iodine, folate, and
other B vitamins, vitamins D and E, magnesium, and
calcium) occur on a global scale and are mirrored by
low intakes from foods and supplements.10,19–27
Despite the absence of established regulatory and
scientific definitions for MVMS, there is agreement
that these products should minimally contain the
vitamins and minerals that are commonly undercon-
sumed relative to their RDA or AI within a country/
region in amounts below the UL. In addition, MVMS
may be safely formulated for specific subgroups accord-
ing to age, sex, and/or life-cycle–specific micronutrient
needs. The decision by HCPs to recommend MVMS
can be individualized based on a person’s diet and risk
for nutrient deficiencies/inadequacies.28 Importantly,
MVMS are considered to be supplements, not
substitutes, for a balanced diet. Indeed, MVMS are
generally perceived by consumers as an “insurance
policy” to help achieve adequate micronutrient intake.
MVMS that maintain intake at or below the RDA or AI
are unlikely to result in excess intake, even when
including the contribution of diet and fortification,
although use of additional supplements might increase
the risk of exceeding the UL.11,29–31
2. Several factors are associated with deficient,
inadequate, or adequate micronutrient intake: bio-
logical functions; cellular, metabolic, or physiological
states; and health outcomes. For some micronu-
trients, higher intakes might provide added health
benefits.
Aþ: 50%; A: 50%
Micronutrients have distinct biological functions,
including serving as essential co-factors to many
enzymes and as structural elements of biological
macromolecules (eg, B vitamins and DNA synthesis),
involvement in one-carbon metabolism, and acting as
hormones and antioxidants.32–35 These biological
functions are essential to metabolic functioning,
growth and development, and many cellular and
organ system functions. In most cases, RDAs and
AIs are based on specific biological or physiological
indicators for each micronutrient to prevent deficiency
diseases/syndromes. For example, Dietary Reference
Intakes (DRIs) of vitamin D and calcium are intended
to promote bone mineral density in adolescents and
reduce loss with aging, and those for folate are linked
to the prevention of megaloblastic anemia and neural
tube defects (NTDs).33,35644When micronutrient intakes are inadequate, subop-
timal cellular/physiological functions can occur in
advance of developing a classic symptomatic deficiency
condition.33 For example, inadequate vitamin A stores
are associated with immunodeficiency. Several other
micronutrients in addition to vitamin A play important
roles in innate and adaptive immunity (eg, vitamin D),
and inadequacies impair normal immune function,
which may increase the risk of infectious diseases and
cancer.33,35 Potassium inadequacies are associated with
hypertension and increased risk of myocardial infarc-
tion and stroke.33,36 Inadequacies in intakes of
folate and vitamin C are associated with biomarkers
indicating an increased risk for hyperhomocysteinemia,
chromosome breakage, chronic inflammation, and
oxidative damage.33,37
Although micronutrient inadequacies are associated
with risk of deficiency and impaired biological func-
tioning, more research is necessary to establish clear
dose–response relationships between biological func-
tional status and health outcomes, taking into consid-
eration interindividual and regional differences in diet,
lifestyle, environment, and genetic variants. This effort
could also clarify apparent increases in function beyond
those associated with deficiencies and inadequacies, as
suggested by studies of higher or “optimal” doses of
vitamins C and D showing apparent improvements in
physiological functioning and risk reduction for age-
related chronic diseases.38–43
3. Achieving micronutrient intake levels on a
population-wide and individual basis that are consis-
tent with established reference values should be an
explicit public health goal.
Aþ: 64%; A: 36%
Human health requires complete and balanced nutri-
tional intake; however, inadequacies in vitamin and
mineral intakes have been widely described, not only in
impoverished and undernourished populations44,45 but
also in developed countries with apparently sufficient
resources.46 Micronutrients are available via the diet,
food fortification, supplementation, or a combination of
these approaches,47 with dietary micronutrient intake
being influenced by numerous factors that change over
time.44
Global recommendations for micronutrient intake
include DRIs, which are developed by the US National
Academy of Medicine48 and Health Canada,12 and
Dietary Reference Values developed by the UKVolume 40 Number 4
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European Union Food Safety Authority,50 and
Nutrient Reference Values developed for Australia
and New Zealand.51 Technical support documents
provide the scientific evidence for recommendations of
each micronutrient and reference values developed to
direct public policy decisions.52,53 The World Health
Organization44 and the Food and Agriculture
Organization of the United Nations54 recognize the
critical role that governments play in setting national
policies to promote adequate nutrient intake and
protect public health. Support for nutrition
guidelines in public policy is also expressed in the
United Nations Sustainable Development Goals to
improve nutrition and protect good health and well-
being.55
Setting public health goals to achieve recommended
micronutrient intakes at individual and population
levels presents challenges with implementation and
monitoring. In setting public policy, these efforts
should appreciate existing knowledge gaps for some
micronutrient recommendations and recognize the
diversity of individuals and populations and their
respective dietary requirements. Consistent with cur-
rent practices, meeting micronutrient needs for indi-
viduals and populations often requires a combination
of improving dietary patterns, fortifying staple foods,
and supplementing the diet with products such as
MVMS. Notably, in some regional programs, focus
on ensuring adequate energy intakes for growth and
development ignores the risk of “hidden hunger,”
which results from inadequate micronutrient intakes
from low-quality diets and adversely affects global
health.56
4. Using a daily MVMS is one way to help provide
the recommended intake levels of many micronutrients
that are necessary for maintaining health through
supporting the function of specific metabolic pathways,
cells, organs, or other physiological systems.
Aþ: 43%; A: 57%
Due to the difficulty in establishing the effect of
MVMS ingredients generally on a given health out-
come, to investigate the role of supplements in
influencing metabolic and physiological systems, evi-
dence was explored via selected illustrations of prior-
ity areas within public health nutrition. These areas
included: (1) folate in early life; (2) B vitamins andApril 2018cognitive health in aging; and (3) vitamin D and
health.
The evidence linking inadequate folate status with
NTDs is conclusive, and other effects of this B vitamin
(and metabolically interrelated B vitamins) throughout
the life cycle are becoming evident.57 Achieving
sufficient folate status and biomarkers thereof is
challenging because natural food folates are
inherently unstable, have limited bioavailability, and
can undergo significant losses before ingestion.58 In
contrast, folic acid (ie, the vitamin form found in
supplements and fortified food) can overcome these
limitations, as it is stable and highly bioavailable.
Therefore, improved folate biomarker status is more
easily achieved by consuming the vitamin through
supplements and fortified food compared with
equivalent intakes of folate from natural food
sources.59,60 In the absence of folic acid fortification
or supplementation, the average diet does not achieve
adequate folate status. Thus, in regions without
mandatory folic acid fortification (eg, European Union
countries), poor compliance with recommendations to
promote folic acid supplements as a policy to prevent
NTDs is reflected in evidence showing no change in
the prevalence of NTDs over the 20 years since the
Medical Research Council Vitamin Study demon-
strated that folic acid prevents recurrence of
NTDs.61–63 Furthermore, using folic acid–containing
MVMS is proven to reduce the incidence of first
occurrence of NTDs64 and is recommended globally
before and in early pregnancy.62,65
Beyond NTDs, supplements containing folate-re-
lated B vitamins (ie, B12, B6, riboflavin) may have
additional benefits, as they are required for normal
folate recycling within one-carbon metabolism. Im-
portant gene–nutrient interactions are also recognized
in these metabolic pathways, and recent research
suggests their impacts on health, such as a novel
interaction of riboflavin with the MTHFR gene that
affects blood pressure regulation.66
Nutritional approaches to slow the progression of
age-related cognitive decline are of increasing public
health interest due to the growing proportion of
elderly people developing these symptoms around
the world. Although certain dietary patterns (eg,
Mediterranean diet) and specific nutrients (eg, n-3
polyunsaturated fatty acids and polyphenols) seem to
be associated with cognitive health in aging,67–69 the645
Clinical Therapeuticstotality of evidence from observational studies and
RCTs seems strongest in supporting roles for folate,
vitamin B12, and vitamin B6 through mechanisms
related to B vitamin–dependent one-carbon metabo-
lism, a network of pathways essential for healthy
cellular functioning, including in the brain.34,70–72
Recent evidence shows that elderly people with lower
B vitamin intake and status have higher rates of
cognitive decline.73 However, additional research is
needed to demonstrate that intervention with B
vitamin supplements can significantly affect cognitive
functioning in older adults.74
Vitamin D supplementation can reduce the risk of
deficiency (serum 25[OH]D o30 nmol/L) and insuffi-
ciency (30–50 nmol/L), which are prevalent glob-
ally.75,76 Vitamin D is essential for bone and muscle
function and immune regulation. The preventive effect
of vitamin D in osteoporosis is well established77;
however, the evidence in other areas, although
provocative, is less clear. Promising observational
evidence supports the role of vitamin D in cognitive
health in older adults, but RCTs to date have not
confirmed this effect.78 Recent evidence from a 4-year
randomized trial of vitamin D plus calcium
supplementation in postmenopausal women did not
reduce the incidence of cancer.79 The results of 3 large
RCTs from the United States, Australia, and Finland
investigating vitamin D supplementation in relation to
cardiovascular disease (CVD) and cancer are expected
in the coming years.80–82
5. On a population basis, use of daily MVMS
reduces the prevalence of inadequate intakes of the
micronutrients they contain.
Aþ: 86%; A: 14%
A MEDLINE search was conducted (1946 to May
2017) to obtain evidence regarding the impact of
supplementation on nutrient inadequacies, using the
following terms: “nutrition surveys” or “diet surveys”
or “nutrient adequacy” combined with “dietary sup-
plements” or “multivitamin supplements.” Among the
634 citations retrieved, 13 reported intakes of multiple
micronutrients by supplement use in national popula-
tion-based samples.
Surveys conducted in the United States, Canada,
Korea, Germany, and Mexico were identified; in
several countries, multiple publications were avail-
able.10,11,29–31,83–91 These studies included adults (n =
10) and/or children (n = 7), and most compared total646nutrient intakes of supplement users and nonusers.
These surveys consistently revealed that supplement
users have higher micronutrient intakes and/or lower
prevalence of inadequacies or intakes below recom-
mended levels.
Two studies analyzing US National Health and
Nutrition Examination Survey datasets specifically
assessed the population prevalence of nutrient inad-
equacies with and without MVMS. Wallace et al10
found that MVMS use (≥1 day per month), compared
with nonuse, significantly reduced the prevalence of
inadequate intakes (assessed as nonoverlapping 95%
confidence intervals [CIs]) of vitamins A, C, D, and E;
calcium; and magnesium. For other micronutrients
(eg, thiamine, riboflavin), the prevalence of
inadequacy was lower with MVMS use but not
statistically significant, in part because of the very
low prevalence of inadequacies regardless of
supplementation. Blumberg et al11 found that in
relation to intake from food alone, MVMS use at
any frequency was associated with a lower prevalence
of inadequacies (P o 0.01) for 15 of the 17
micronutrients examined. Significant (P o 0.01)
increases in the prevalence of intakes exceeding the
UL for 7 micronutrients were observed, but the
prevalence was ≤4% for any micronutrient. Except
for calcium, magnesium, and vitamin D, the most
frequent category of MVMS use (≥21 days per
month) virtually eliminated inadequacies of the
nutrients examined. Furthermore, MVMS use was
associated with significantly lower odds ratios (ORs)
of deficiency for all the examined nutrient biomarkers
except for iron.
6. Based on current knowledge, the long-term use
of MVMS with an amount not exceeding the UL is
safe in healthy adults.
Aþ: 71%; A: 29%
The safety of micronutrients is dependent on their
intakes falling between recommended levels and ULs.
In an analysis of data from the US National Health
and Nutrition Examination Survey (N ¼ 16,444),
MVMS reduced the percentage of the population with
nutrient intakes below the Estimated Average Re-
quirement but did not cause excess intake.10 In users
of MVMS, the prevalence of those exceeding the UL
was 1.7% for retinol and 2.5% for folic acid. Indeed,
even if fortified food and beverages are considered, it
seems unlikely that intakes will exceed the UL in theVolume 40 Number 4
J.B. Blumberg et al.long term. For determining safety, both the amount
supplied and the length of use within different age
groups should be determined.
Few studies exist that document long-term use and
specifically evaluate adverse events (AEs). A review by
Simpson et al92 reported 6 studies of MVMS that used
biological safety data from children and adults and
reported no clinically meaningful AEs or abnormal
blood tests related to toxicity. AE data from 157
children and adults revealed only minor, transitory
reports of headache and nausea. One study that
directly compared the safety of supplements and
conventional psychiatric medications found no
clinically meaningful abnormal laboratory values
among its 88 pediatric and adult subjects. The
supplement group experienced significantly fewer
AEs (P ≤ 0.026) and less weight gain (P o 0.0001).
In the Physicians’ Health Study (PHS) II, the only
RCT that has addressed the safety of long-term
MVMS use versus placebo, no significant differences
were found on gastrointestinal symptoms (eg,
peptic ulcer, constipation, diarrhea, gastritis, nausea),
fatigue, drowsiness, skin discoloration, or migraine.93
A systematic review of RCTs by Biesalski and Tinz94
addressed safety of MVMS; 9 studies evaluated use
of MVMS in pregnant women and healthy adults,
and 6 studies explicitly assessed AEs in the elderly. Only
minor AEs (eg, unspecific gastrointestinal symptoms)
were reported, and there were no significant differences
between groups. Based on current knowledge, the long-
term use of MVMS (410 years) with doses not
exceeding ULs seems to be safe.
7. The evidence that long-term use of MVMS
contributes to a reduction in the risk of some chronic
diseases is insufficient to support the use of MVMS in
the primary prevention of these diseases.
Aþ: 64%; A: 29%; U: 7%
In the 21st century, the global burden of disease and
associated mortality will continue to be driven primar-
ily by CMCs.95 The World Health Organization’s
Global Action Plan for the Prevention and Control
of Noncommunicable Diseases proposes policies to
increase consumption of fresh fruits and vegetables
and reduce energy-rich, micronutrient-poor foods.96
Evidence from basic research and observational studies
indicates that dietary factors, including micronutrients,
are key components for preventing the development of
CMCs, including some forms of cancer.97April 2018In observational studies, the relationship between
the total intake of micronutrients at dietary levels
and the incidence of CMCs (eg, cancer, CVD,
age-related eye diseases) has been shown primarily
to be null, and in some instances, positive and
even negative associations were reported.98 In a
meta-analysis of 13 cohort studies conducted by
Park et al,99 an aggregate analysis of individuals
enrolled in 10 studies using MVMS for 7 to 20
years found a decreased risk of colon cancer
(relative risk [RR], 0.88; 95% CI, 0.81–0.96)
versus nonusers. A meta-analysis of cohort studies
conducted by Ye and Song100 found a modest risk
reduction in CVD associated with higher intakes of
vitamins C and E and β-carotene. Results from the
prospective Nurses' Health Study showed that long-
term use (415 years) of MVMS (with folic acid) was
associated with a decreased risk of colon cancer
(RR, 0.25; 95% CI, 0.13–0.51) versus nonuse.101
A long-term prospective cohort study of subjects
enrolled in PHS I found no association between
MVMS use and most assessed cardiovascular
outcomes, although a 14% decrease was observed in
cardiovascular revascularization risk (hazard ratio
[HR], 0.86; 95% CI, 0.75–0.98) versus nonuse. In
addition, a self-reported history of ≥20 years’ MVMS
use was associated with a 44% reduction in risk for
CVD (HR, 0.56; 95% CI, 0.35–0.90).102
Similar to observational studies, RCTs of MVMS
use and chronic disease risk have shown mixed results.
A meta-analysis of RCTs conducted by Fortman
et al103 indicated that long-term MVMS use
(11.2–12.5 years) reduced the incidence of cancer
(RR, 0.94; 95% CI, 0.89–1.00) versus placebo. Two
studies included in this meta-analysis (PHS II93 and
Supplementation en Vitamines et Mineraux
Antioxydants [SU.VI.MAX]104) individually found a
reduction in cancer risk and mortality in men. In PHS
II, a significant 8% reduction in total cancer incidence
was observed versus placebo (HR, 0.92; 95% CI,
0.86–0.998), as well as an 18% reduction in total
cancer incidence in men aged ≥70 years (HR, 0.82;
95% CI, 0.72–0.93).93 In the total population, the
risk for cancer development was 12% lower with
MVMS use compared with placebo when prostate
cancer was excluded (HR, 0.88; 95% CI, 0.79–0.98).
The greatest total cancer risk reduction was observed
in the total population of men with baseline cancer
histories (HR, 0.73; 95% CI, 0.56–0.96), but no647
Clinical Therapeuticsbenefit was observed for specific cancer types (ie,
prostate, lung, colorectal, and pancreatic, for which
PHS II was insufficiently powered).
Another meta-analysis by Fortman et al103 reported
no significant effect of MVMS for reducing CVD risk
(RR, 1.02; 95% CI, 0.94–1.10) based on the results of
PHS II and SU.VI.MAX. Other MVMS meta-analyses
that evaluated CVD have also primarily reported null
outcomes. Six reviews or meta-analyses, principally of
RCTs, that evaluated combinations of vitamins C and
E, β-carotene, and selenium found no effect on the
primary or secondary prevention of CVD.105–110
Similarly, SU.VI.MAX, which included 13,017 French
men and women who received a combination of
vitamins C and E, β-carotene, selenium, and zinc,
found no significant overall benefit versus placebo in
ischemic CVD (RR, 0.97; 95% CI, 0.77–1.20).111
However, the overall mortality risk was significantly
lower in men (RR, 0.63; 95% CI, 0.42–0.93) but not
in women (RR, 1.03; 95% CI, 0.64–1.63). In 2
analyses from PHS II, no reduction in major
cardiovascular events was observed with higher
doses of vitamin C or E for 8 years or MVMS for
11 years,112,113 but a significant reduction in myocar-
dial infarction death (HR, 0.61; 95% CI, 0.38–0.995)
was observed with the MVMS.113
PHS II also evaluated subjects on age-related eye
disease outcomes and reported a reduction in cataract
development (HR, 0.91; 95% CI, 0.83–0.99) and
cataract surgeries (HR, 0.89; 95% CI, 0.80–0.99)
versus placebo.114 Similarly, in the Age-Related Eye
Disease Study (AREDS), a risk reduction for any lens
(OR, 0.88; 95% CI, 0.79–0.98) or nuclear opacity
(OR, 0.78; 95% CI, 0.68–0.89) was observed in users
of MVMS versus nonusers.115 The Italian-American
Clinical Trial of Nutritional Supplements and Age-
Related Cataract administered MVMS for 9 years (N
¼ 1020) and reported a decrease in nuclear opacity
progression among a population with early or no
cataracts.116 The AREDS supplement containing
vitamins C and E plus zinc, copper, and β-carotene
reduced the risk for loss of visual acuity and
progression to advanced age-related macular
degeneration (ARMD) versus placebo.117
Despite the promising data in this area, several
observational studies and RCTs have failed to show
that MVMS decrease the risk of CMCs. However,
some studies conducted with supra-dietary doses of
individual micronutrients have indicated the potential648for harm (eg, an increased risk of lung cancer with 20
mg β-carotene in the Alpha-Tocopherol, Beta Caro-
tene Cancer Prevention Study118 and an association
between high vitamin B6 single supplements and lung
cancer in the Vitamins and Lifestyle Study cohort119).
Long-term use of MVMS at doses approximating
recommended intakes has been shown to be safe.94
The totality of these data, therefore, is insufficient to
support using MVMS for CMC prevention.
8. MVMS use in populations with inadequate
intakes or increased needs of micronutrients can
provide benefits to apparently healthy individuals,
including children, pregnant women, and older adults.
Aþ: 36%; A: 50%; U: 14%
Searches for systematic reviews and meta-analyses
published in the past 5 years were conducted by using
the following criteria: population (adults, children,
pregnant women); interventions (MVMS, vitamin D,
iron at supplement doses); comparisons (no MVMS);
and outcomes (growth, pregnancy outcomes, intelli-
gence/cognition, psychological features, cataracts,
safety).
Children
Administration of MVMS and supplements con-
taining vitamin A and zinc can improve linear growth
in school-aged children and cognitive performance in
children likely to be deficient in micronutrients but
otherwise healthy.120,121 A meta-analysis by Roberts
and Stein120 examined baseline height-for-age z score,
subject age, nutrient dose, and study duration for
heterogeneity in 69 RCTs, most of which were
conducted in low- and middle-income countries.
Zinc (17 studies and 19 datasets; mean effect size
[ES], 0.15; 95% CI, 0.06–0.24), vitamin A (5 studies
and 16 datasets; mean ES, 0.05; 95% CI, 0.01–
0.09), and ≥2 of any micronutrients (17 studies;
mean ES, 0.26; 95% CI, 0.13–0.39) had positive
effects on linear growth, but iron, calcium, iodine,
and food-based interventions did not. Baseline age,
study duration, and dose were not predictors of ES for
any nutrient examined. A systematic review of 19
RCTs by Lam and Lawlis121 conducted with data
primarily from developing countries and children
experiencing deficiencies found that micronutrients
positively affected fluid intelligence (ie, problem
solving, logic). No meta-analysis was possible owing
to differences in reporting. No consistent effect onVolume 40 Number 4
J.B. Blumberg et al.crystallized intelligence (memory), attention, or school
performance was found. An examination of MVMS
use in infants was not conducted.Healthy Adults
A meta-analysis of 8 MVMS RCTs conducted by
Long and Benton122 reported a reduction in minor
psychiatric symptoms among healthy adults. Perceived
stress (standard mean difference [SMD], 0.35; 95%
CI, 0.47–0.22; P ¼ 0.001), mild psychiatric symptoms
(SMD, 0.30; 95% CI, 0.43–0.18; P ¼ 0.001), and
subclinical anxiety (SMD, 0.32; 95% CI, 0.48–0.16; P
o 0.001) were reduced compared with placebo, but
subclinical depression was not (SMD, 0.20; 95% CI,
0.42–0.03; P ¼ 0.089). Fatigue (SMD, 0.27; 95% CI,
0.40–0.146; P o 0.001) and confusion (SMD, 0.225;
95% CI, 0.38–0.07; P o 0.003) were also reduced
compared with placebo.Pregnant and Breastfeeding Women
Two Cochrane reviews examined MVMS versus iron
and/or folic acid supplementation alone during preg-
nancy. Haider and Bhutta123 identified 19 RCTs
conducted in predominantly low- and middle-income
countries (United Kingdom, 2 studies; France, 1 study).
A significant reduction in low-birth-weight infants was
found with MVMS versus iron and/or folic acid (RR,
0.88; 95% CI, 0.85–0.91), but no differences were found
in preterm births or stillbirths, neonatal death,
miscarriage, or operative delivery risk. Balogun et al124
indicated that taking any vitamin supplements before or
during early pregnancy did not decrease miscarriage rates.
A meta-analysis of 31 observational studies and 4
RCTs conducted by Wolf et al125 evaluated the
effect of MVMS on pregnancy outcomes in
developed countries. Using the GRADE (Grades of
Recommendation Assessment, Development, and
Evaluation) criteria, the quality of evidence was
assessed as low or very low for all outcomes except
for NTD recurrence, for which a moderate benefit was
found. MVMS use did not change the risk for preterm
birth (RR, 0.84; 95% CI, 0.69–1.03). However, the
risk of small for gestational age infants (RR, 0.77;
95% CI, 0.63–0.93), NTDs (RR, 0.67; 95% CI,
0.52–0.87), cardiovascular defects (RR, 0.83; 95%
CI, 0.70–0.98), urinary tract defects (RR, 0.60; 95%
CI, 0.46–0.78), and limb deficiencies (RR, 0.68;
95% CI, 0.52–0.89) decreased.April 2018Vitamin D alone (200–2000 IU/d) or single doses of
60,000 to 600,000 IU were examined in a Cochrane
review conducted by De-Regil et al.126 Data from
477 women (3 RCTs) indicate that vitamin D
supplementation during pregnancy reduces the incidence
of preterm birth (8.9%) versus no intervention or placebo
(15.5%; RR, 0.36; 95% CI, 0.14–0.93; moderate
quality). Data from 493 women (3 RCTs; 1 of the
aforementioned trials and 2 others) also revealed that
vitamin D supplementation during pregnancy reduces the
frequency of having a low-birth-weight infant (o 2500 g)
compared with no intervention or placebo (RR, 0.40;
95% CI, 0.24–0.67; moderate quality).
Calcium supplementation alone has also been
studied at doses typically formulated in MVMS. A
Cochrane review by Hofmeyr et al127 found a small
effect of calcium supplementation on pre-eclampsia
risk, but these studies were small and the risk for
hemolysis, elevated liver enzyme levels, and low
platelets increased with supplementation.Older Adults
A Cochrane review that examined vitamin D
supplementation versus placebo or no intervention
found a decrease in mortality when all 56 trials were
analyzed together (5920 of 47,472 [12.5%] vs 6077
of 47,814 [12.7%]; RR, 0.97; 95% CI, 0.94–0.99;
P ¼ 0.02; I2 ¼ 0%).128 However, these studies were
of low to moderate quality due to considerable
attrition and the relatively short duration of some
studies, and a sensitivity analysis suggested that the
result should be considered with caution. A meta-
analysis of 24 RCTs by Forbes et al129 involving
interventions including B vitamins, vitamin E, or
omega-3 fatty acids evaluated cognitive function and
found no statistically significant effect on Mini–
Mental State Examination or digit span forward
scores. There is evidence, primarily from cohort
studies, that MVMS may reduce cataract risk.130
9. Some individuals with CMCs experience nutri-
tional deficiencies and/or inadequacies that can be
prevented and treated with adequate dietary manage-
ment and/or the use of MVMS.
Aþ: 86%; A: 14%
The evidence reviewed here included studies iden-
tified through a PubMed search; diverse ranges of
search terms related to MVMS and some specific
CMCs were included.649
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In the AREDS 2 study, 1 supplement replaced
β-carotene with lutein and zeaxanthin, and a signifi-
cant benefit (P ¼ 0.01) was observed in slowing the
progression to advanced ARMD in patients with low
dietary intake of these carotenoids and either current
bilateral large drusen or large drusen in 1 eye and
advanced ARMD in the other eye.131 In the Lutein
Antioxidant Supplementation Trial, subjects with
existing atrophic ARMD who received lutein alone
or combined with antioxidants showed improvements
in visual function after 1 year.132
Women’s Health
Female infertility treatment has been shown to im-
prove with micronutrient supplementation, particularly
with combinations of folic acid; vitamins B6, C, and D;
iodine; selenium; iron; and/or omega-3 fatty acids.133 In a
small pilot study, MVMS have shown better results
versus folic acid alone in ovulation induction among
women undergoing fertility treatment.134 Osteopenia and
osteoporosis are prevalent in postmenopausal women,
and optimization of vitamin D and calcium intake is
recommended for managing individuals with these
conditions due to their role in maintaining bone
mineral density and reducing the risk of falling135,136;
however, those at highest risk of subsequent fractures will
likely require additional pharmacologic and nonpharma-
cologic treatments.
Obesity
Deficiencies or inadequacies in vitamin B6, C, D,
and E can occur among obese individuals,137 and
many weight-loss diets can cause micronutrient
inadequacies.138 Furthermore, body mass index has
been shown to be associated with poor folate status in
nonpregnant women of childbearing age, suggesting
that obesity may modify folate metabolism.139
Bariatric surgery can also cause or exacerbate
micronutrient deficiencies, especially vitamin B12 and
iron, and this risk is higher with gastric bypass
procedures that involve food malabsorption.140 After
bariatric surgery (particularly Roux-en-Y gastric
bypass), dietary patterns do not improve to an ideal
level.141 Vitamin D deficiency after bariatric surgery is
common and must be treated to reduce osteoporosis
risk.142 Preventing micronutrient deficiencies is
believed to be critical to bariatric surgery success.143
This scenario may be particularly important for obese650women of childbearing potential who may be at an
increased risk for key nutrient deficiencies and
inadequacies related to negative pregnancy outcomes
(eg, NTDs).144 Although most patients receive post–
bariatric-surgery MVMS and report improvements in
their nutritional status and prevention of anemia,
there is a large disparity in the prevalence of this
practice.145,146 Furthermore, MVMS may not provide
adequate nutritional support,147 and individual
supplements at higher doses may be necessary for
certain individuals.
Type 2 Diabetes Mellitus
Levels of vitamins A, C, and E, thiamine, pyridoxine,
and biotin can be reduced in type 2 diabetes mellitus
(T2DM), and metformin treatment impairs the bioavail-
ability of vitamin B12 and folic acid.
148,149 Metformin
also negatively affects vitamin B12 status in patients with
polycystic ovary syndrome.150 Most MVMS studies in
patients with diabetes have shown inconclusive results
on disease progression and its sequelae, although
MVMS improved micronutrient status.148 However, a
meta-analysis of RCTs that evaluated magnesium
supplementation reported improvements in insulin
resistance.151 An RCT conducted in patients with
T2DM who received MVMS with a zinc supplement
reported improvements in glycemic control and lipid
profile versus placebo.152DISCUSSION
Health care research and policy development are
primarily driven by the paradigm of evidence-based
medicine. However, certain facets of nutrition re-
search regarding health promotion and disease pre-
vention, as implemented, do not fit well within this
context; in particular, reliance on RCTs as the “gold
standard” for evidence-based policy.153–156 For exam-
ple, although nutritional status at baseline and dietary
variability during the RCTs (especially when these
factors are not assessed) can significantly affect the
interpretation of results, these are often overlooked in
the analysis. In addition, dietary supplements,
MVMS in particular, typically provide doses that
approximate recommended intake levels and would
only produce modest changes, albeit with potentially
large public health benefits. Inappropriately conflating
expectations regarding health outcomes of nutritional
interventions can lead to confusion among HCPsVolume 40 Number 4
J.B. Blumberg et al.and incorrect conclusions, and findings arising from
the research can often be misrepresented in the lay
media, resulting in misunderstandings by the public.
The conflicting evidence associated with the use and
benefits of MVMS helps reveal several gaps in our
knowledge base and provides a rationale for convening
this consensus panel. As suggested in these summaries,
although the essentiality of micronutrients in human
biology and health is well understood, additional
research is necessary to fully elucidate the role of
MVMS for maintaining and promoting health and
preventing CMCs. Despite certain limitations associated
with various research approaches in several of the
studies described here, there is a clear indication that,
within the general population, appropriately formu-
lated MVMS can safely provide essential micronutrients
to help individuals achieve recommended intake lev-
els.28,94 However, when recommending any dietary
supplement to a patient, it is important that HCPs
consider individual factors, including dietary micro-
nutrient intakes, to avoid exceeding ULs of nutrients
that may cause adverse effects when overconsumed. As
noted earlier, MVMS should not be viewed as sub-
stitutes for a balanced diet but should be recommended,
in addition to other advice for a healthy lifestyle, to
ensure adequate micronutrient intake and status.CONCLUSIONS
This consensus panel has indicated that MVMS can
improve the micronutrient intake and, hence, the
nutritional status of individuals presenting with defi-
ciencies and inadequacies, including those with CMCs.
However, the effect of MVMS on the primary pre-
vention of CMCs is presently inconclusive, despite
some modest yet promising results from RCTs. Impor-
tantly, there is a clear indication that the long-term use
of MVMS formulated with doses that do not exceed
ULs is safe; however, additional research is necessary to
fully define the benefits of MVMS for health promotion
and disease prevention. Consumers and clinicians
should therefore consider the risks of deficiencies and
the potential benefits of supplementation. Given the
relatively low cost and established safety of MVMS, as
well as the essentiality of adequate micronutrient status
for human biology and good health, HCPs should
assess their patients’ dietary needs and risk of micro-
nutrient inadequacies and consider intervening with
MVMS for their at-risk patients.April 2018CONFLICTS OF INTEREST
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